Welcome to our dedicated page for China Pharma Holdings news (Ticker: CPHI), a resource for investors and traders seeking the latest updates and insights on China Pharma Holdings stock.
China Pharma Holdings, Inc. (NYSE American: CPHI) is a pharmaceutical company headquartered in Haikou, China. The company specializes in the development, manufacturing, and marketing of pharmaceutical products targeted at high-incidence and high-mortality diseases prevalent in the People's Republic of China. Its core business revolves around producing a variety of dosage forms including dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.
China Pharma’s diverse product portfolio consists of well-known drugs such as cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, and ozagrel sodium for injection, among others. A recent notable achievement is the receipt of the 'Drug Supplementary Application Approval Notice' from the National Medical Products Administration (NMPA) of China for its candesartan tablets, signifying their quality and efficacy consistency with generic drugs.
The company has also taken significant steps in the medical device sector. For instance, its Dry Eye Disease (DED) therapeutic device recently passed third-party testing and is preparing for market launch approval. This highlights China Pharma’s commitment to diversifying its offerings and addressing a broad spectrum of medical needs in China.
Financially, China Pharma operates a cost-effective business model driven by market demand and supported by new GMP-certified product lines. The company’s extensive and expanding nationwide distribution network ensures a robust presence across all major cities and provinces in China. The company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., plays a pivotal role in its manufacturing capabilities.
China Pharma continues to expand its market presence and competitive edge by participating in China’s national centralized procurement, enhancing its potential for growth in government procurement sectors. The company remains focused on improving public health outcomes through affordable and effective medication, while also aiming to generate significant value for its shareholders.
For more information, please visit www.chinapharmaholdings.com.
On December 1, 2022, China Pharma Holdings, Inc. (NYSE American: CPHI) received a notification from NYSE American regarding noncompliance with listing standards due to insufficient stockholders' equity, reported at $2.8 million as of September 30, 2022. This falls below the $4.0 million minimum required after reporting net losses for four consecutive fiscal years. If compliance is not achieved by December 15, 2023, delisting proceedings may commence. The Company remains operational and its stock will continue to trade while it seeks compliance.
On September 26, 2022, China Pharma Holdings, Inc. (NYSE American: CPHI) received a Deficiency Letter from NYSE American for failing to meet listing standards. The letter indicated that the company's stock has traded below $0.20 on average for the past 30 days, as of September 22, 2022. The company must either conduct a reverse stock split or demonstrate sustained price improvement by March 26, 2023. The notification does not impact the company’s operations or obligations under SEC regulations. CPHI aims to regain compliance with the listing standards.
On July 15, 2022, China Pharma Holdings, Inc. (NYSE American: CPHI) submitted a compliance plan to NYSE American to address stockholders' equity deficiencies identified in a June 15, 2022 letter. The company must demonstrate compliance with Section 1003(a)(iii) by December 15, 2023. CEO Zhilin Li expressed optimism, noting the NYSE's acceptance of the compliance plan. China Pharma focuses on critical health conditions in China, supported by a strong distribution network and GMP-certified products.
On June 15, 2022, China Pharma Holdings, Inc. (NYSE American: CPHI) received a noncompliance notice from NYSE American regarding its listing standards. The Company must submit a compliance plan by July 15, 2022 to address deficiencies and regain compliance by December 15, 2023, or face potential delisting. The stock will remain listed but will carry a '.BC' designation indicating noncompliance. Despite this, the notification does not affect the Company’s operations or SEC reporting obligations.
China Pharma Holdings, Inc. (CPHI) reported fiscal year 2021 results, showing a revenue decline to $9.6 million from $10.9 million in 2020, largely due to price pressure from centralized drug procurement policies. Gross margin fell to 3.7% from 18.0%, contributing to a net loss of $3.4 million. Operating loss increased to $2.9 million. The company noted challenges from COVID-19 and expressed optimism regarding Hainan Free Trade Port policies. Cash and cash equivalents rose to $4.9 million, but an audit opinion raised concerns about the company's going concern status.
China Pharma Holdings, Inc. (CPHI) reported a 17.6% revenue decline to $2.0 million for Q3 2021, down from $2.4 million in Q3 2020. This drop is attributed to national drug price reductions. The net loss decreased to $0.8 million, compared to $1.0 million a year ago, primarily due to lower selling expenses. For the nine months ended September 30, 2021, revenue was $6.8 million, also down from $7.9 million in 2020, with a net loss of $2.4 million. The company remains optimistic about growth opportunities in specialty pharma and TCM amid favorable policies.
China Pharma Holdings, Inc. (CPHI) reported a 35.9% decline in revenue to $2.4 million for Q2 2021, compared to $3.8 million in Q2 2020, primarily due to a one-time sale of COVID-19 testers in the previous year. The company incurred a net loss of $0.8 million, a drop from a net income of $0.01 million in the same period last year. However, excluding this one-time deal, sales increased 15% year-over-year. The company has repaid a significant loan, reducing future cash flow pressures. Overall, CPHI remains optimistic about opportunities in specialty pharmaceuticals and Traditional Chinese Medicine.
China Pharma Holdings, Inc. (NYSE American: CPHI) announced that its Candesartan hypertension product successfully passed bioequivalence tests. The company intends to leverage these results to apply for National Medical Products Administration (NMPA) approval in China. Chairman and CEO Zhilin Li emphasized the significant demand for Candesartan, given hypertension's global health impact. The product aims to help control high blood pressure, which affects over a billion people worldwide and is a leading cause of death. A successful NMPA approval could enhance market reach and sales opportunities for the company.
China Pharma Holdings, Inc. (NYSE American: CPHI) announced plans to launch a highly purified NMN+PQQ product after a successful pilot scale test. NMN, a derivative of niacin, is believed to improve health by replenishing NAD+ levels that decline with age, potentially aiding cardiovascular function and wellness. CEO Zhilin Li emphasized the product's alignment with their healthcare category and market demand, indicating that it could enhance revenue stability. The company plans to leverage the Hainan Free Trade Port for sales and may seek partnerships for global distribution.
China Pharma Holdings, Inc. (NYSE American: CPHI) reported a 33.7% increase in revenue to $2.4 million for Q1 2021, up from $1.8 million a year earlier, primarily due to recovery from COVID-19 and favorable exchange rates. The company achieved a gross margin of 11.6%, slightly up from 11.0% in Q1 2020. However, the net loss widened to $0.8 million due to increased R&D investments. The company's CEO highlighted optimism for growth driven by a diversified product portfolio and upcoming product launches in compliance with Hainan Free Trade Port policies.
FAQ
What is the current stock price of China Pharma Holdings (CPHI)?
What is the market cap of China Pharma Holdings (CPHI)?
What does China Pharma Holdings, Inc. do?
Where is China Pharma Holdings, Inc. based?
What are some of the products offered by China Pharma?
What recent achievement has China Pharma made?
What is the significance of the NMPA approval for China Pharma?
What is China Pharma's business model?
How extensive is China Pharma's distribution network?
What new product is China Pharma planning to launch?
When will the reverse stock split for China Pharma be effective?
How can I find more information about China Pharma Holdings, Inc.?
